[LorenPechtel]

And it's something the FDA shouldn't be allowing.

You want to bring a new drug to market, you should be required to demonstrate that it's not strictly inferior to existing options in at least some patients. I'm fine with a head-to-head that comes out a tie (competition is good for the marketplace) and I'm fine with a drug that only works in a subset if that subset can be identified. And I'm fine with a drug that doesn't work as well but is more tolerated. I'm not fine with a drug that loses in all respects in a head-to-head.

[throwup238]

That's far too strict. It doesn't do anyone any good to reject less effective drugs unless the safety to efficacy ratio is way off. Most drugs are relatively safe compared to the diseases they treat and identifying the subset that they work for is beyond our capability at the moment (i.e. the entirety of psychiatric medicine).

The FDA drug/therapy pipeline is supposed to give downstream users like doctors, public health officials, and patients more options within a certain risk profile. They're not supposed to be the be-all-end-all of treatment options.

[LorenPechtel]

Just because a drug is relatively safe doesn't mean it should be allowed if it's inferior to the existing one in all respects.

[throwup238]

They are never inferior to existing ones in all respects for one very obvious reason: allergies.

If you’re allergic to drug A but not drug B, it doesn’t matter how much better A is than B. You need drug B.

All drugs have the potential to cause allergic reactions or other nasty side effects so unless a drug is too dangerous on its own, it should be allowed. It’s absolutely critical to deal with biochemical diversity in humans.

[LorenPechtel]

Good point, but many of the me-too drugs are chemically close enough to the original to cross-react. (And in some cases are actually identical--a company finds a compound the body will convert into the original drug.)